A U.S.-based angel investment group invests in seed-stage life sciences and technology companies. The firm’s typical initial investment ranges from $100,000 to $250,000, structured as either secured convertible debt with interest and a discount upon conversion to preferred shares, or direct investments in preferred equity. Geographically, the firm focuses on opportunities in the United States, Canada, and Israel.
Within life sciences, the investor is primarily interested in early-stage medical devices and diagnostics. The firm is flexible regarding technology types and therapeutic indications, provided the solutions address meaningful medical needs. The investor also considers therapeutics companies, with a preference for those that have reached the early clinical stage. The firm generally avoids investments in purely digital applications.
The firm does not have specific company or management team requirements and can provide active advisory support to portfolio companies as needed. The investor prefers to co-invest alongside larger investment groups rather than lead financing rounds and seeks companies with a clear potential exit pathway within three to five years.
If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.
